Literature for PKF275-055 (S09.003 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2016

Fiordaliso,F., Maggioni,S., Balconi,G., Schiarea,S., Corbelli,A., De Luigi,A., Figliuzzi,M., Antoniou,X., Chiabrando,C., Masson,S., Cervo,L. and Latini,R. Effects of dipeptidyl peptidase-4 (DPP-4) inhibition on angiogenesis and hypoxic injury in type 2 diabetes Life Sci (2016) 154, 87-95. PubMed Europe PubMed DOI I

2014

Kodera,R., Shikata,K., Takatsuka,T., Oda,K., Miyamoto,S., Kajitani,N., Hirota,D., Ono,T., Usui,H.K. and Makino,H. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes Biochem Biophys Res Commun (2014) 443, 828-833. PubMed Europe PubMed DOI I

2012

Akarte,A.S., Srinivasan,B.P. and Gandhi,S. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates beta-cell proliferation resulting in improved glucose homeostasis in diabetic rats Biochem Pharmacol (2012) 83, 241-252. PubMed Europe PubMed DOI I
Akarte,A.S., Srinivasan,B.P., Gandhi,S. and Sole,S. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats Eur J Pharm Sci (2012) 47, 456-463. PubMed Europe PubMed DOI I
Bianchi,R., Cervellini,I., Porretta-Serapiglia,C., Oggioni,N., Burkey,B., Ghezzi,P., Cavaletti,G. and Lauria,G. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy J Pharmacol Exp Ther (2012) 340, 64-72. PubMed Europe PubMed DOI I
Terasaki,M., Nagashima,M., Watanabe,T., Nohtomi,K., Mori,Y., Miyazaki,A. and Hirano,T. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice Metabolism (2012) 61, 974-977. PubMed Europe PubMed DOI I